Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
Br J Clin Pharmacol. 2012 Jan;73(1):140-3. doi: 10.1111/j.1365-2125.2011.04048.x.
We compared three times daily dual therapy with standard triple therapy for effectiveness and safety in H. pylori infection.
Two hundred and four H. pylori positive patients with peptic ulcer were randomly assigned to one of two regimens: (i) triple therapy with amoxicillin, clarithromycin and lansoprazole twice daily for 2 weeks or (ii) dual therapy with amoxicillin and lansoprazole three times daily for 2 weeks. The success of eradication was evaluated 4 to 5 weeks after completing treatment.
The eradication rate was 82.8% in the triple therapy group and 78.4% in the dual therapy group by per protocol analysis. This difference was not significant (P= 0.573). Adverse events were more frequent in the triple therapy group than in the dual therapy group (P= 0.002).
Because dual therapy had fewer side effects than triple therapy and a similar eradication rate, dual therapy may provide an acceptable alternative first line therapy for H. pylori eradication in Korea.
我们比较了每日三联疗法与标准三联疗法治疗幽门螺杆菌感染的疗效和安全性。
将 204 例消化性溃疡的幽门螺杆菌阳性患者随机分为两组:(i)每日三联疗法,即阿莫西林、克拉霉素和兰索拉唑每日 2 次,持续 2 周;(ii)每日 3 次的双重疗法,即阿莫西林和兰索拉唑每日 3 次,持续 2 周。治疗结束后 4-5 周评估根除效果。
按意向性分析,三联疗法组的根除率为 82.8%,双重疗法组为 78.4%。两组之间的差异无统计学意义(P=0.573)。三联疗法组的不良反应发生率高于双重疗法组(P=0.002)。
由于双重疗法的副作用比三联疗法少,根除率相似,因此在韩国,双重疗法可能是一种可接受的幽门螺杆菌根除的一线替代治疗方法。